Home HOME Neoplasma 2021 Neoplasma Vol.68, No.6, p.1132–1138, 2021

Journal info

6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.68, No.6, p.1132–1138, 2021

Title: Research progress on the treatment of advanced prostate cancer with Olaparib
Author: Yi-Xin Su, Cheng-Feng Yu, Peng Xue, Lin-Lu Li, Kun-Min Xiao, Xue-Lei Chu, Shi-Jie Zhu

Abstract: Prostate cancer (PCa) is one of the most common malignancies in men worldwide, and metastatic castrate-resistant prostate cancer (mCRPC) has shown a poor prognosis. Although chemotherapy and androgen deprivation therapy (ADT) have improved clinical outcomes, the median survival (MS) of patients with mCRPC is still less than 2 years. With the development of poly adenosine diphosphate-ribose polymerase inhibitor (PARPi), the treatment strategy for patients with mCRPC has markedly evolved. Olaparib, a type of PARPi that can selectively induce synthetic lethality in cancer cells with homologous recombination (HR) deficiencies, was the first type of PARPi approved for treating patients with mCRPC harboring mutations in HR repair (HRR) genes. This review discusses and summarizes the latest progress on therapeutic mechanisms, monotherapy, combination therapy, and adverse events of Olaparib.

Keywords: Olaparib; advanced prostate cancer; research progress; homologous recombination repair; synthetic lethality
Published online: 15-Nov-2021
Year: 2021, Volume: 68, Issue: 6 Page From: 1132, Page To: 1138

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.